ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion: new indication

Clesrovimab (Enflonsia)

New indication (Respiratory Syncytial Virus Vaccines). The wording is on the EMA page.

CHMP opinion 12 Nov 2026 · Merck Sharp Dohme Limited
EU · EU licence (European Commission)

Clesrovimab (Enflonsia)

Enflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Enflonsia should be used in accordance with official recommendations.

CHMP opinion 18 Sept 2025 → EU licence 15 Apr 2026 · Merck Sharp Dohme Limited
US · FDA approval, new medicine

Clesrovimab-cfor (Enflonsia)

To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season

Approved 9 Jun 2025

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.